CBO Data Suggest Medicare Inflation Rebates Will Lower Commercial Drug Prices

By John Wilkerson / September 13, 2022 at 3:51 PM
Medicare drug price controls will lower prices for private insurance, too, according to a Council for Informed Drug Spending Analysis analysis of Congressional Budget Office data, and CBO's score might make it difficult to get Congress to eventually extend government price controls to the commercial market. The new drug pricing law directs Medicare to negotiate drug prices, and Medicare charges drug makers rebates when they raise prices faster than inflation. Democrats wanted to give Medicare drug prices to the commercial...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.